Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
Abstract
GLP-1 stimulates insulin secretion, suppresses glucagon secretion, delays gastric emptying, and inhibits small bowel motility, all actions contributing to the anti-diabetogenic peptide effect. Endothelial dysfunction is strongly associated with insulin resistance and type 2 diabetes mellitus and may cause the angiopathy typifying this debilitating disease. Therefore, interventions affecting both endothelial dysfunction and insulin resistance may prove useful in improving survival in type 2 diabetes patients. We investigated GLP-1's effect on endothelial function and insulin sensitivity (S I ) in two groups: 1) 12 type 2 diabetes patients with stable coronary artery disease and 2) 10 healthy subjects with normal endothelial function and S I . Subjects underwent infusion of recombinant GLP-1 or saline in a random crossover study. Endothelial function was measured by postischemic FMD of brachial artery, using ultrasonography. S I [in (10 −4 dl·kg −1 ·min −1 )/(μU/ml)] was measured by hyperinsulinemic isoglycemic clamp technique. In type 2 diabetic subjects, GLP-1 infusion significantly increased relative changes in brachial artery diameter from baseline FMD(%) (3.1 ± 0.6 vs. 6.6 ± 1.0%, P < 0.05), with no significant effects on S I (4.5 ± 0.8 vs. 5.2 ± 0.9, P = NS). In healthy subjects, GLP-1 infusion affected neither FMD(%) (11.9 ± 0.9 vs. 10.3 ± 1.0%, P = NS) nor S I (14.8 ± 1.8 vs. 11.6 ± 2.0, P = NS). We conclude that GLP-1 improves endothelial dysfunction but not insulin resistance in type 2 diabetic patients with coronary heart disease. This beneficial vascular effect of GLP-1 adds yet another salutary property of the peptide useful in diabetes treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GLP-1 has beneficial effects on left ventricular function after acute myocardial infarction and on vasodilatation in healthy subjects and patients with type II DM and stable coronary disease.
“it has beneficial effects on left ventricular function after acute myocardial infarction (29) and on vasodilatation in healthy subjects and patients with type II DM and stable coronary disease (6, 32).”
From Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans (2008) · cites this paper as [32]
Human studies provide conflicting information about the effect of GLP-1 or stable analogues on endothelial function.
“Human studies provide conflicting information about the effect of GLP-1 or stable analogues on endothelial function.212-217”
From The Vasculature in Prediabetes (2018) · cites this paper as [214]
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961 · see citing works
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965 · see citing works
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064 · see citing works
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · see citing works
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
Celermajer, D. S., Sorensen, K. E., Gooch, V. M., Spiegelhalter, D. J., Miller, O. I., Sullivan, I. D., Lloyd, J. K., & Deanfield, J. E. (1992) · The Lancet · doi:10.1016/0140-6736(92)93147-f · Cited by 4,742 · see citing works
Corretti, M. C., Anderson, T. J., Benjamin, E. J., Celermajer, D. S., Charbonneau, F., Creager, M. A., Deanfield, J. E., Drexler, H., Gerhard‐Herman, M. D., Herrington, D. M., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01746-6 · Cited by 4,606 · see citing works
Close Relation of Endothelial Function in the Human Coronary and Peripheral Circulations
Anderson, T. J., Uehata, A., Gerhard, M. D., Meredith, I. T., Knab, S., Delagrange, D., Lieberman, E. H., Ganz, P., Creager, M. A., Yeung, A. C., et al. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00327-4 · Cited by 2,033 · cited 1× · see citing works
“Furthermore, endothelial dysfunction of FMD in the brachial artery highly correlates with endothelial dysfunction in the coronary circulation (2).”
BackgroundSteinberg, H. O., Chaker, H., Leaming, R., Johnson, A., Brechtel, G., & Baron, A. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118709 · Cited by 1,687 · cited 1× · see citing works
“It has become increasingly clear that insulin also has vasoactive properties that are NO dependent (28) and diminished in insulin-resistant states (29).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works
Self-citationSteinberg, H. O., Brechtel, G., Johnson, A., Fineberg, N. S., & Baron, A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117433 · Cited by 1,219 · see citing works
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · see citing works
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · see citing works
Self-citationDiabetes and Endothelial Dysfunction: A Clinical Perspective
Calles-Escandón, J., & Cipolla, M. J. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.1.0417 · Cited by 657 · see citing works
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/endo.137.7.8770921 · Cited by 618 · see citing works
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J., Lopez, M. E., Hollenberg, A., Baggio, L., Saper, C., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15595 · Cited by 544 · see citing works
Fehmann, H. C., Göke, R., & Göke, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 527 · see citing works
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429 · see citing works
Endothelial Dysfunction in Obesity and Insulin Resistance: A Road to Diabetes and Heart Disease
Caballero, A. E. (2003) · Obesity Research · doi:10.1038/oby.2003.174 · Cited by 416 · see citing works
Wendelhag, I., Liang, Q., Gustavsson, T., et al. (1997) · Stroke · doi:10.1161/01.str.28.11.2195 · Cited by 376 · see citing works
Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339 · see citing works
Self-citationCreutzfeldt, W., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 328 · see citing works
Self-citationAntihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
Yu, M., Moreno, C., Hoagland, K. M., Dahly, A., Ditter, K., Mistry, M., & Roman, R. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00012 · Cited by 292 · see citing works
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
Nauck, M. A., Wollschläger, D., Werner, J., Holst, J. J., Ørskov, C., Creutzfeldt, W., & Willms, B. (1996) · Diabetologia · doi:10.1007/s001250050613 · Cited by 283 · see citing works
Self-citationBarragán, J., Rodríguez, R. E., & Blázquez, E. (1994) · American Journal of Physiology · doi:10.1152/ajpendo.1994.266.3.e459 · Cited by 207 · see citing works
Golpon, H. A., Püchner, A., Welte, T., von Wichert, P., & Feddersen, C. O. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(01)00300-7 · Cited by 158 · see citing works
GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery
Richter, G., Feddersen, O. C., Wagner, U., Barth, P. J., Göke, R., & Göke, B. (1993) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1993.265.4.l374 · Cited by 146 · see citing works
Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes
Nauck, M. A., Holst, J. J., Willms, B., & Schmiegel, W. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211750 · Cited by 145 · see citing works
Self-citationBarragán, J. M., Eng, J., Rodríguez, R., & Blázquez, E. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.5.e784 · Cited by 142 · see citing works
Tolessa, T., Gutniak, M., Holst, J. J., Efendic, S., & Hellström, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci942 · Cited by 139 · see citing works
Self-citationÅhrén, B., Larsson, H., & Holst, J. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3728 · Cited by 135 · see citing works
Self-citationGlucagon-Like Peptide-1 Augments Insulin-Mediated Glucose Uptake in the Obese State
Egan, J. M., Meneilly, G. S., Habener, J. F., & Elahi, D. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8743 · Cited by 119 · see citing works
GLP-1 does not acutely affect insulin sensitivity in healthy man
Ørskov, L., Holst, J. J., Møller, J., Ørskov, C., Møller, N., Alberti, K. G. M. M., & Schmitz, O. (1996) · Diabetologia · doi:10.1007/bf02658511 · Cited by 114 · see citing works
Self-citationPotential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet
Gutniak, M., Larsson, H., Heiber, S. J., Juneskans, O. T., Holst, J. J., & Åhrén, B. (1996) · Diabetes Care · doi:10.2337/diacare.19.8.843 · Cited by 99 · see citing works
Self-citationJohansson, B., Wahren, J., & Pernow, J. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00001.2003 · Cited by 45 · see citing works
Fernqvist‐Forbes, E., Johansson, B., & Eriksson, M. J. (2001) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.2001.00860.x · Cited by 30 · see citing works
Drugs on the Horizon for Treatment of Type 2 Diabetes
Rachman, J., & Turner, R. C. (1995) · Diabetic Medicine · doi:10.1111/j.1464-5491.1995.tb00526.x · Cited by 26 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · see citing works
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · see citing works
Self-citationGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · see citing works
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · see citing works
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · see citing works
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746 · see citing works
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · see citing works
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · see citing works
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403 · see citing works
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407 · see citing works
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388 · see citing works
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358 · see citing works
Management of diabetes and hyperglycaemia in the hospital
Pasquel, F. J., Lansang, M. C., Dhatariya, K., & Umpierrez, G. E. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30381-8 · Cited by 329 · see citing works
Martín-Peláez, S., Fito, M., & Castaner, O. (2020) · Nutrients · doi:10.3390/nu12082236 · Cited by 330 · see citing works
GLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312 · see citing works
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302 · see citing works
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298 · see citing works
Crajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00729.2010 · Cited by 278 · see citing works
Shiraki, A., Oyama, J.-I., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., Kodama, K., Sakamoto, Y., Kotooka, N., Hirase, T., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.039 · Cited by 263 · see citing works
Nagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259 · see citing works
Hendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232 · see citing works
Basu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R., & Joyner, M. J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00373.2007 · Cited by 226 · see citing works
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204 · see citing works
Chai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z. (2012) · Diabetes · doi:10.2337/db11-1073 · Cited by 194 · see citing works
Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186 · see citing works
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · see citing works
RetractedLiu, L., Liu, J., Wong, W. T., Tian, X. Y., Lau, C. W., Wang, Y.-X., Xu, G., Pu, Y., Zhu, Z., Xu, A., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195115 · Cited by 179 · see citing works
Wang, D., Luo, P., Wang, Y., Li, W., Wang, C., Sun, D., Zhang, R., Su, T., Ma, X., Zeng, C., et al. (2013) · Diabetes · doi:10.2337/db12-1025 · Cited by 179 · see citing works
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175 · see citing works
Koska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174 · see citing works
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171 · see citing works
Tashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149 · see citing works
Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148 · see citing works
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143 · see citing works
Wei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., Liu, Y., Hou, W., Feng, X., Wang, G., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00400.2015 · Cited by 137 · see citing works
The Vasculature in Prediabetes
Wasserman, D. H., Wang, T. J., & Brown, N. J. (2018) · Circulation Research · doi:10.1161/circresaha.118.311912 · Cited by 137 · see citing works
Ceriello, A., Esposito, K., Testa, R., Bonfigli, A. R., Marra, M., & Giugliano, D. (2011) · Diabetes Care · doi:10.2337/dc10-1949 · Cited by 134 · see citing works
Tremblay, A. J., Lamarche, B., Deacon, C. F., Weisnagel, S. J., & Couture, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.004 · Cited by 132 · see citing works
Fisman, E. Z., & Tenenbaum, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01412-5 · Cited by 124 · see citing works
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121 · see citing works
GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441526 · Cited by 104 · see citing works
Aronis, K. N., Chamberland, J. P., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.04.010 · Cited by 104 · see citing works
Bharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98 · see citing works
Goldney, J., Sargeant, J. A., & Davies, M. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05988-3 · Cited by 100 · see citing works
Kelly, A. S., Bergenstal, R. M., Gonzalez-Campoy, J., Katz, H., & Bank, A. J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-64 · Cited by 98 · see citing works
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99 · see citing works
Glucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99 · see citing works
Effects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97 · see citing works
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99 · see citing works
Shi, L., Ji, Y., Jiang, X., Zhou, L., Xu, Y., Li, Y., Jiang, W., Meng, P., & Liu, X. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0177-4 · Cited by 91 · see citing works
Inoue, K., Maeda, N., Kashine, S., Fujishima, Y., Kozawa, J., Hiuge-Shimizu, A., Okita, K., Imagawa, A., Funahashi, T., & Shimomura, I. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-109 · Cited by 89 · see citing works
Xiao-Yun, X., Zhao-Hui, M., Ke, C., Hong-Hui, H., & Yan-Hong, X. (2011) · Medical Science Monitor · doi:10.12659/msm.881383 · Cited by 88 · see citing works
Fayfman, M., Galindo, R. J., Rubin, D. J., Mize, D. L., Anzola, I., Urrutia, M. A., Ramos, C., Pasquel, F. J., Haw, J. S., Vellanki, P., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1760 · Cited by 85 · see citing works
Garg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82 · see citing works
Chai, W., Zhang, X., Barrett, E. J., & Liu, Z. (2014) · Diabetes · doi:10.2337/db13-1597 · Cited by 73 · see citing works
Faurschou, A., Knop, F. K., Thyssen, J. P., Zachariae, C., Skov, L., & Vilsbøll, T. (2014) · Acta Diabetologica · doi:10.1007/s00592-011-0359-9 · Cited by 65 · see citing works
Pinelli, N. R., & Hurren, K. M. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q024 · Cited by 59 · see citing works
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Dozier, K. C., Cureton, E. L., Kwan, R. O., Curran, B., Sadjadi, J., & Victorino, G. P. (2009) · Peptides · doi:10.1016/j.peptides.2009.06.019 · Cited by 58 · see citing works
GLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55 · see citing works
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56 · see citing works
Tesauro, M., Schinzari, F., Adamo, A., Rovella, V., Martini, F., Mores, N., Barini, A., Pitocco, D., Ghirlanda, G., Lauro, D., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0763 · Cited by 54 · see citing works
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Kang, Y. M., & Jung, C. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.258 · Cited by 51 · see citing works
Chai, W., Fu, Z., Aylor, K. W., Barrett, E. J., & Liu, Z. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00205.2016 · Cited by 51 · see citing works
Bertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49 · see citing works
Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease
Triggle, C. R., Ding, H., Marei, I., Anderson, T. J., & Hollenberg, M. D. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0677 · Cited by 49 · see citing works
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47 · see citing works
Tang, S.-T., Zhang, Q., Tang, H.-Q., Wang, C.-J., Su, H., Zhou, Q., Wei, W., Zhu, H.-Q., & Wang, Y. (2016) · Endocrine · doi:10.1007/s12020-015-0852-y · Cited by 46 · see citing works
Self-citationDirect cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45 · see citing works
Forst, T., Weber, M. M., & Pfützner, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/635472 · Cited by 44 · see citing works
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43 · see citing works
Love, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13045 · Cited by 40 · see citing works
Gurkan, E., Tarkun, I., Sahin, T., Cetinarslan, B., & Canturk, Z. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.046 · Cited by 38 · see citing works
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 33 · see citing works
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33 · see citing works
Hopkins, N. D., Cuthbertson, D. J., Kemp, G. J., Pugh, C., Green, D. J., Cable, N. T., & Jones, H. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12089 · Cited by 31 · see citing works
Role of Glucose-Lowering Medications in Erectile Dysfunction
Cignarelli, A., Genchi, V. A., D’Oria, R., Giordano, F., Caruso, I., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112501 · Cited by 30 · see citing works
Liu, J., Aylor, K. W., & Liu, Z. (2023) · Diabetes · doi:10.2337/db22-0745 · Cited by 30 · see citing works
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25 · see citing works
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24 · see citing works
Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
Yamada, S., Ogura, Y., Inoue, K., Tanabe, J., Sugaya, T., Ohata, K., Nagai, Y., Natsuki, Y., Hoshino, S., Watanabe, S., et al. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111472 · Cited by 25 · see citing works
Augestad, I. L., Dekens, D., Karampatsi, D., Elabi, O., Zabala, A., Pintana, H., Larsson, M., Nyström, T., Paul, G., Darsalia, V., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15524 · Cited by 21 · see citing works
Self-citationGlucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
Wroge, J., & Williams, N. T. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016663218 · Cited by 17 · see citing works
Korakas, E., Kountouri, A., Pavlidis, G., Oikonomou, E., Vrentzos, E., Michalopoulou, E., Tsigkou, V., Katogiannis, K., Pliouta, L., Balampanis, K., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae122 · Cited by 18 · see citing works
Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists
Reed, J., Kanamarlapudi, V., & Bain, S. (2018) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000147 · Cited by 16 · see citing works
Garczorz, W., Francuz, T., Siemianowicz, K., Kosowska, A., Kłych, A., Aghdam, M. R. F., & Jagoda, K. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.08.007 · Cited by 12 · see citing works
Aulinger, B., & D'Alessio, D. (2007) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328013e79e · Cited by 8 · see citing works
Shepherd, A. I., Wilkerson, D. P., Dobson, L., Kelly, J., Winyard, P. G., Jones, A. M., Benjamin, N., Shore, A. C., & Gilchrist, M. (2015) · Nitric Oxide · doi:10.1016/j.niox.2015.01.002 · Cited by 88 · see citing works
- Authors
- Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å.
- Affiliations
- Karolinska Institutet (SE)
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2004-12
- Volume
- 287
- Issue
- 6
- Pages
- E1209-E1215
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2129730863
- Cited by
- 680
- References
- 36
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 20 · 2023: 14 · 2022: 22 · 2021: 25 · 2020: 25 · 2019: 24 · 2018: 26 · 2017: 32 · 2016: 35 · 2015: 51 · 2014: 61 · 2013: 60 · 2012: 56
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Physiology-Endocrinology and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glucagon-like peptide-1, endothelial dysfunction, type 2 diabetes, stable coronary artery disease, insulin sensitivity, insulin resistance, flow-mediated dilation, brachial artery, diabetic vascular disease
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Brachial Artery, Coronary Circulation, Coronary Disease, Coronary Vessels, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Endothelium, Vascular, Glucagon, Nitroglycerin, Humans, Insulin, Male, Middle Aged, Peptide Fragments, Pilot Projects, Protein Precursors, Regional Blood Flow, Vasodilation, Receptors, Glucagon, Cross-Over Studies, Endothelial Cells, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
